Aspirin and Vascepa are two different medications with different mechanisms of action and indications. Aspirin is a nonsteroidal anti-inflammatory drug (NSAID) commonly used to relieve pain, reduce inflammation, and prevent blood clotting [1]. Vascepa, on the other hand, is a prescription medication that contains the active ingredient icosapent ethyl and is used to reduce the risk of cardiovascular events in certain adult patient groups [2].

Regarding the interaction between aspirin and Vascepa, there is limited information available. The sources provided do not specifically mention any direct interaction between these two medications. However, it is important to note that both medications can have antiplatelet effects, which means they can help prevent blood clotting [1][2]. Aspirin is well-known for its antiplatelet properties and is often prescribed for this purpose [1]. Vascepa, although primarily used for cardiovascular risk reduction, may also have some antiplatelet effects [2].

When considering the combination of aspirin and Vascepa, it is crucial to consult with a healthcare professional. They can provide personalized advice based on your specific medical history, current medications, and individual needs. They will consider the potential benefits and risks associated with using these medications together and make recommendations accordingly.

In summary, the available sources do not provide specific information on how aspirin affects Vascepa's effectiveness. Both medications have antiplatelet properties, but it is important to consult with a healthcare professional for personalized advice on their combined use.

Sources:
[1] DrugPatentWatch. (n.d.). Aspirin - Tradename: Aspirin. Retrieved from https://www.drugpatentwatch.com/p/tradename/ASPIRIN
[2] Healthline. (n.d.). Vascepa. Retrieved from https://www.healthline.com/health/drugs/vascepa
[3] FDA. (2019, December 13). FDA approves use of drug to reduce risk of cardiovascular events in certain adult patient groups. Retrieved from https://www.fda.gov/news-events/press-announcements/fda-approves-use-drug-reduce-risk-cardiovascular-events-certain-adult-patient-groups